Step 3: Hit Identification

  1. Simeonov, A., Yasgar, A., Jadhav, A., Lokesh, G. L., Klumpp, C., Michael, S., Austin, C. P., Natarajan, A.*, Inglese, J. “Dual-Fluorophore Quantitative High-throughput Screen for Inhibitors of BRCT-Phosphoprotein Interaction” Anal. Biochem. 2008, 375(1), 60-70. PMCID: PMC3389998.

  2. Kumar, E. A., Charvet, C. D., Lokesh, G. L., Natarajan, A.* “High throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-PTK interactions” Anal. Biochem. 2011, 411(2), 254-260. PMCID: PMC3078584.

  3. Palermo, N. Y., Natarajan, A.* “Beyond the frog: The evolution of homology models of human IKKβ” Bioorg. Med. Chem. Lett. 2011, 21(20), 6081-6084. PMCID: PMC3177977.

  4. Yuan, Z., Kumar, E. A., Kizhake, S., Natarajan, A.* “Structure activity relationship studies to probe the phosphoprotein binding site on the BRCT domains of BRCA1” J. Med. Chem. 2011, 54(12), 4264-4268. PMCID: PMC3117075.

  5. Kumar, E. A., Yuan, Z., Palermo, N. Y., Dong, L., Ahmad, G., Lokesh, G. L., Kolar, C., Kizhake, S., Borgstahl, G. E. O., Band, H., Natarajan, A.* “Peptide truncation leads to a twist and an unusual increase in affinity for Cbl tyrosine kinase binding domain” J. Med. Chem. 2012, 55(7), 3583-3587. PMCID: PMC3325325.

  6. Rana, S., Blowers, E. B., Tebbe, C., Contreras, J. I., Radhakrishnan, P., Kizhake, S., Zhou, T., Rajule, R. N., Arnst, J. L., Munkarah, A., Rattan, R., Natarajan, A.* “Isatin derived spirocyclic analogs with α-methylene-γ-butyrolactone as anticancer agents: A structure activity relationship study” J. Med. Chem. 2016, 59, 5121-27. PMCID: PMC5273401.

  7. Sonawane, Y. A., Zhu, Y., Garrison, G., Ezell, E., Zahid, M., Cheng, X., Natarajan, A.* “Structure activity relationship studies with tetrahydroquinoline analogs as EPAC inhibitors" ACS Med. Chem. Lett., 2017, 8, 1183-1187. PMCID: PMC5774307.

  8. Contreras, J. I., Robb, C. M., King, H. M., Baxter, J., Crawford, A. J., Kour, S., Kizhake, S., Rana, S., Sonawane, Y. A., Luo, X., Natarajan, A.* “Chemical genetic screens identify kinase inhibitor combinations that target anti-apoptotic proteins for cancer therapy” ACS Chem. Biol. 2018, 13, 1148-1152. PMCID: PMC6119178.

  9. Rana, S., Kour, S., Sonawane, Y. A., Robb, C. M., Contreras, J, I., Kizhake, S., Zahid, M., Karpf, A. R., Natarajan, A.*“Symbiotic Prodrugs (SymProDs) Dual Targeting of NFkappaB and CDK” Chem. Biol. Drug Des. 2020, 96, 773. PMCID: PMC8022330.

  10. Sagar, S., Singh, S., Mallareddy, J. R., Sonawane, Y. A., Napoleon, J. V., Rana, S., Contreras, J. I., Rajesh, C., Ezell, E. L., Kizhake, S., Garrison, J. C., Radhakrishnan, P., Natarajan, A.* “Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy” Eur. J. Med. Chem. 2021, 222(113579) 1-15. PMCID: PMC8373685.

4. Hit Validation